| Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma (NCT05326243) | Pell Bio-Med Technology Co., Ltd. | 2022-05-31 |
| PD-L1 PET-imaging During CAR T-cell Therapy (NCT05404048) | University Medical Center Groningen | 2022-05-18 |
| CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol (NCT05648019) | KK Women's and Children's Hospital | 2022-03-15 |
| Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting (NCT05108805) | Vanderbilt-Ingram Cancer Center | 2021-12-02 |
| CAR-T Followed by Bispecific Antibodies (NCT04889716) | Abramson Cancer Center at Penn Medicine | 2021-11-05 |
| NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers (NCT05020678) | Nkarta, Inc. | 2021-08-20 |
| Study of Efficacy of BZ019 in Large B-cell Lymphoma (NCT05472610) | Shanghai Mengchao Cancer Hospital | 2021-06-04 |
| CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma (NCT04690192) | Institute of Hematology & Blood Diseases Hospital, China | 2021-01-01 |
| Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity (NCT04503538) | Wake Forest University Health Sciences | 2020-12-01 |
| Sequential CD19/CD22 CAR-T Cell Therapy Following ASCT (NCT07236151) | The First Affiliated Hospital of Soochow University | 2020-02-24 |
| Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma (NCT04250324) | Shanghai Cell Therapy Group Co.,Ltd | 2019-11-19 |
| Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL (NCT03960840) | Novartis Pharmaceuticals | 2019-06-26 |
| MT2017-45: CAR-T Cell Therapy for Heme Malignancies (NCT03642626) | Masonic Cancer Center, University of Minnesota | 2018-12-18 |
| Risk Adapted Therapy in Diffuse Large B Cell Lymphoma (NCT03188198) | Mansoura University | 2016-06-01 |
| Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma (NCT00118209) | Alliance for Clinical Trials in Oncology | 2005-05-01 |
| Expanded Access Program for Epcoritamab (NCT05733650) | Genmab | |
| Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel (NCT05776160) | Kite, A Gilead Company | |